OR

Browse By

Professor David Fairlie

NHMRC Leadership Fellow and Group L

Institute for Molecular Bioscience
d.fairlie@uq.edu.au
+61 7 334 62989

Overview

Professor Fairlie is an NHMRC Research Investigator Fellow (Level 3) (2022-present), a Node Leader of the ARC Centre of Excellence for Innovations in Peptide Protein Science, one of four Centre Directors and former Head of the Division of Chemistry of Structural Biology at the Institute for Molecular Bioscience (since 2009), and an Affiliate Professor of the School of Chemistry and Molecular Biosciences. He was previously an NHMRC Senior Principal Research Fellow (2012-2021), a Node Leader at the ARC Centre of Excellence in Advanced Molecular Imaging (2014-2021), an ARC Federation Fellow (2006-2011), an ARC Professorial Fellow (2002-2006), and Scientific Director and Chief Scientific Officer of a startup company. He undertook postdoctoral studies at Stanford University and University of Toronto, postgraduate studies at Australian National University and University of New South Wales, and undergraduate studies at University of Adelaide.

His research group works across the disciplines of chemistry (synthesis, structure, reaction mechanisms), biochemistry (enzyme inhibitors, protein-protein interactions, GPCRs, transcription factors), immunology (innate immune cells in health and disease, mucosal T cells), and pharmacology (molecular pharmacology and human cell signalling, experimental pharmacology in rodent models of human diseases). He has published over 450 scientific journal articles in high impact chemistry journals (e.g. Chem Rev, J Am Chem Soc, Angew Chem Int Edit, Chem Sci, J Med Chem, Org Lett, J Org Chem) and biology journals (e.g. Nature, Science, Nature Immunology, Immunity, Science Immunology, Nature Communications, J Exp Med, J Clin Invest, Proc Natl Acad Sci, Diabetes, Cancer Res, Br J Pharmacol). He has been a Highly Cited Researcher (Clarivate Analytics), with over 37,000 citations and 104 publications with over 100 citations (Google Scholar), and has collaborated with many of the world’s largest pharmaceutical and biotechnology companies.

Research Interests

  • Biochemistry and Protein-Protein Interactions
    One strategic theme is the development of small molecules to mimic or inhibit bioactive protein surfaces recognized by other proteins. Protein-protein interactions drive most biological processes, yet the vast majority of these interactions occur over very short time scales (fractions of seconds). To better understand such fleeting interactions, we have been developing mimics of protein surfaces and working towards studying their longer-lived interactions with protein partners. We have identified conformations of protein surfaces that are common recognition elements for protease enzymes, for classes of G protein-coupled receptors that act as sensors on cell surfaces, or for transcriptional receptors that mediate DNA-protein responses in cells. We have described small molecules that structurally and functionally mimic components of bioactive protein surfaces (beta strands, beta-sheets, beta and gamma turns, alpha helices, helix bundles, multi-loop bundles). There are numerous potential uses for each of these classes of protein surface mimics - with many potential therapeutic applications. Through the ARC Centre of Excellence for Innovations in Peptide and Protein Science, we are studying post-translational modifications of proteins, elucidating structures and activities of naturally occurring peptides, and designing and developing peptidomimetics with interesting chemical or biological properties.
  • Immunology
    We aim to better understand the molecular basis of the immune response and study aspects of innate and adaptive immunity. Our group works with human neutrophils, macrophages, dendritic cells, mast cells, complement and T cells, investigating their recruitment, differentiation, signalling and modulation in immunity, including the effects of novel drug leads on their functions. We are especially interested in complement proteins, GPCRs, T cell receptors, proteases, HDACs, chemokines and cytokines. Our novel compounds are used to validate targets on human cells and human proteins, then investigated in rodent models of human diseases and then towards preclinical and clinical studies, sometimes with pharma/biotech partners. Understanding how new experimental drugs can stimulate/enhance immune responses or suppress proinflammatory mediators can help in the design and development of effective new therapies to combat a diverse range of important human diseases. Through the ARC Centre of Excellence in Advanced Molecular Imaging, we linked up with physicists, structural biologists and immunologists in Melbourne and Sydney to study the molecular basis of T cell mediated immunity. Through collaborations with the IMB Centre for Inflammation and Disease Research in Brisbane, we study innate immunity.
  • Molecular and Experimental Pharmacology
    Our research on diseases involves basic, strategic and applied research in biochemistry and pharmacology directed at: (1) understanding how the immune system resolves infection (by parasites, viruses, bacteria) and tissue injury; (2) how prolonged inflammatory responses can cause debilitating chronic inflammatory diseases, including onset of cancers, metabolic diseases (obesity, type 2 diabetes, atherosclerosis, cardiovascular diseases), chronic inflammatory pain, and neurodegenerative diseases (e.g. Alzheimer's disease); and (3) how our novel compounds can act on human proteins, human and rodent cells and tissues, and rat or mouse models of human diseases. See links for our publications in all of these disease areas and allied chemical, biochemical and pharmacological research. We conduct molecular pharmacology (studies of novel ligand interactions with cellular receptors, modulation of intracellular signalling pathways using experimental new drugs discovered in our labs, mechanisms of physiological responses and disease induction/progression) and experimental pharmacology (studies of drug-induced effects in rodent models of human diseases, interrogating molecular mechanisms in vivo, examining human tissues from the clinic). Our goal is to discover new drugs, mechanisms of drug action and to understand disease development and how to treat it.
  • Chemistry and Human Therapeutics
    The Fairlie group works at the interface of chemistry, biology and disease. We study CHEMISTRY, BIOCHEMISTRY, PHARMACOLOGY and IMMUNOLOGY to better understand the detailed processes of life, ageing, disease and death. Our chemists use state of the art methods to invent new compounds that regulate enzymes, protein-protein interactions, cellular receptors, RNA or DNA. Our biochemists, cell biologists, pharmacologists and immunologists study enzymes, proteins, cells and rodents to understand biological processes and effects of novel compounds in models of human diseases. We elucidate mechanisms of chemical reactions, biological processes, disease development and drug action. We aim to develop new treatments for human inflammatory and respiratory diseases, cancers, metabolic diseases (type 2 diabetes, obesity, cardiovascular), viral infections and neurodegenerative disorders (e.g. Alzheimer’s disease). We also execute basic research to understand fundamental principles and processes in chemistry (medicinal, organic, biological, computational, bioinorganic), biochemistry (proteins, enzymes), pharmacology (cells, rodents, human tissues) and immunology (neutrophils, macrophages, mast cells, dendritic cells, complement, T cells, rodents).
  • Medicinal and Organic Chemistry
    We develop skills in chemical synthesis, structure elucidation and chemical mechanisms. We design new molecules with the aid of computers, develop new methods to synthesize them, determine their structures, elucidate reaction mechanisms, and use small molecules to probe biological processes and to elucidate structure-activity relationships. We use a wide range of solution and solid phase organic synthesis methodologies to create bioactive molecules (e.g. de novo designed drugs, natural product analogues, and peptidomimetics), reactive intermediates, highly functionalised molecular templates, structural constraints, and artificial receptors. We are engaged in chemical design and structural analysis using computers, determination of chemical structures by NMR spectroscopy and X-ray crystallography, spectroscopic investigations of chemical and biological reactions, enzyme kinetics, cell biology, and molecular pharmacology in vitro and in vivo.

Research Impacts

Our researchers work at interfaces of chemistry and biology to better understand the molecular mechanisms of life, ageing, disease and death.

Our chemists study organic, medicinal and biological chemistry, especially using organic synthesis, computer-aided molecular design, nuclear magnetic resonance spectroscopy to create new chemical structures that interact with or mimic protein surfaces. We discover new chemical structures, reactions and mechanisms; enzyme inhibitors, agonists and antagonists of protein function; and molecules that mimic the structures and functions of bioactive protein surfaces.

Our biologists study mechanisms of protein and cell activation, signalling pathways, biological processes, disease development and drug action. We use novel experimental compounds discovered in our group as molecular tools to interrogate the functions of human proteins and cells, and apply some of them to the treatment of animal models of human diseases.

Our interdisciplinary expertise can be combined across multiple subdisciplines of chemistry and biology to gain insights into biochemical processes, human physiology, disease pathology, and we develop skills in biochemistry, pharmacology, virology, immunology, oncology or neurobiology. We work, in some cases with industry partners, to discover new basic research and apply some of our discoveries to develop experimental treatments for viral or parasitic infections, such as HIV, dengue fever and malaria; inflammatory diseases, such as arthritis, asthma, inflammatory bowel disease and rare immunological disorders; metabolic and cardiovascular disorders linked to obesity and type 2 diabetes; neurodegenerative diseases and cancers.

Qualifications

  • PhD, University of New South Wales
  • BSc(Hons), The University of Adelaide

Publications

  • Journal Article: Achiral derivatives of hydroxamate AR-42 potently inhibit class I HDAC enzymes and cancer cell proliferation

    Tng, Jiahui, Lim, Junxian, Wu, Kai-Chen, Lucke, Andrew J., Xu, Weijun, Reid, Robert C. and Fairlie, David P. (2020). Achiral derivatives of hydroxamate AR-42 potently inhibit class I HDAC enzymes and cancer cell proliferation. Journal of Medicinal Chemistry, 63 (11) acs.jmedchem.0c00230, 5956-5971. doi: 10.1021/acs.jmedchem.0c00230

  • Journal Article: The molecular basis underpinning the potency and specificity of MAIT cell antigens

    Awad, Wael, Ler, Geraldine J. M., Xu, Weijun, Keller, Andrew N., Mak, Jeffrey Y. W., Lim, Xin Yi, Liu, Ligong, Eckle, Sidonia B. G., Le Nours, Jérôme, McCluskey, James, Corbett, Alexandra J., Fairlie, David P. and Rossjohn, Jamie (2020). The molecular basis underpinning the potency and specificity of MAIT cell antigens. Nature Immunology, 21 (4), 400-411. doi: 10.1038/s41590-020-0616-6

  • Journal Article: A novel long-range n to π* interaction secures the smallest known α-helix in water

    Hoang, Huy N., Wu, Chongyang, Hill, Timothy A., Dantas de Araujo, Aline, Bernhardt, Paul V., Liu, Ligong and Fairlie, David P. (2019). A novel long-range n to π* interaction secures the smallest known α-helix in water. Angewandte Chemie International Edition, 58 (52) ange.201911277, 18873-18877. doi: 10.1002/anie.201911277

  • Journal Article: Alpha-synuclein structure and Parkinson's disease - Lessons and emerging principles

    Meade, Richard M., Fairlie, David P. and Mason, Jody M. (2019). Alpha-synuclein structure and Parkinson's disease - Lessons and emerging principles. Molecular Neurodegeneration, 14 (1) 29, 29. doi: 10.1186/s13024-019-0329-1

  • Journal Article: Inhibitors of class I histone deacetylases attenuate thioacetamide-induced liver fibrosis in mice by suppressing hepatic Type 2 inflammation

    Loh, Zhixuan, Fitzsimmons, Rebecca L., Reid, Robert C., Ramnath, Divya, Clouston, Andrew, Gupta, Praveer K., Irvine, Katharine M., Powell, Elizabeth E., Schroder, Kate, Stow, Jennifer L., Sweet, Matthew J., Fairlie, David P. and Iyer, Abishek (2019). Inhibitors of class I histone deacetylases attenuate thioacetamide-induced liver fibrosis in mice by suppressing hepatic Type 2 inflammation. British Journal of Pharmacology, 176 (19) bph.14768, 3775-3790. doi: 10.1111/bph.14768

  • Journal Article: Twists or turns: stabilising alpha vs. beta turns in tetrapeptides

    Hoang, Huy N., Hill, Timothy A., Ruiz-Gómez, Gloria, Diness, Frederik, Mason, Jody M., Wu, Chongyang, Abbenante, Giovanni, Shepherd, Nicholas E. and Fairlie, David P. (2019). Twists or turns: stabilising alpha vs. beta turns in tetrapeptides. Chemical Science, 10 (45), 10595-10600. doi: 10.1039/c9sc04153b

  • Journal Article: Glucuronic acid as a helix-inducing linker in short peptides

    Wu, Chongyang, Hoang, Huy N, Liu, Ligong and Fairlie, David P (2018). Glucuronic acid as a helix-inducing linker in short peptides. Chemical Communications, 54 (17), 2162-2165. doi: 10.1039/c7cc09785a

  • Journal Article: Exploiting a novel conformational switch to control innate immunity mediated by complement protein C3a

    Lohman, Rink-Jan, Hamidon, Johan K., Reid, Robert C., Rowley, Jessica A., Yau, Mei-Kwan, Halili, Maria A., Nielsen, Daniel S., Lim, Junxian, Wu, Kai-Chen, Loh, Zhixuan, Do, Anh, Suen, Jacky Y., Iyer, Abishek and Fairlie, David P. (2017). Exploiting a novel conformational switch to control innate immunity mediated by complement protein C3a. Nature Communications, 8 (1) 351, 351. doi: 10.1038/s41467-017-00414-w

  • Journal Article: Stabilizing short-lived Schiff base derivatives of 5-aminouracils that activate mucosal-associated invariant T cells

    Mak, Jeffrey Y. W., Xu, Weijun, Reid, Robert C., Corbett, Alexandra J., Meehan, Bronwyn S., Wang, Huimeng, Chen, Zhenjun, Rossjohn, Jamie, McCluskey, James, Liu, Ligong and Fairlie, David P. (2017). Stabilizing short-lived Schiff base derivatives of 5-aminouracils that activate mucosal-associated invariant T cells. Nature Communications, 8 (1) 14599, 14599. doi: 10.1038/ncomms14599

  • Journal Article: Electrophilic helical peptides that bond covalently, irreversibly, and selectively in a protein-protein interaction site

    Dantas De Araujo, Aline, Lim, Junxian, Good, Andrew C., Skerlj, Renato T. and Fairlie, David P. (2017). Electrophilic helical peptides that bond covalently, irreversibly, and selectively in a protein-protein interaction site. ACS Medicinal Chemistry Letters, 8 (1), 22-26. doi: 10.1021/acsmedchemlett.6b00395

  • Journal Article: Membrane-anchored serine protease matriptase is a trigger of pulmonary fibrogenesis

    Bardou, Oliver, Menou, Awen, Francois, Charlene, Duitman, Jan Willem, von der Thusen, Jan H., Borie, Raphael, Sales, Katiuchia Uzzun, Mutze, Kathrin, Castier, Yves, Sage, Edouard, Liu, Ligong, Bugge, Thomas H., Fairlie, David P., Konigshoff, Melanie, Crestani, Bruno and Borensztain, Keren S. (2015). Membrane-anchored serine protease matriptase is a trigger of pulmonary fibrogenesis. American Journal of Respiratory and Critical Care Medicine, 193 (8), 847-860. doi: 10.1164/rccm.201502-0299OC

  • Journal Article: Improving on nature: making a cyclic heptapeptide orally bioavailable

    Nielsen, Daniel S., Hoang, Huy N., Lohman, Rink-Jan, Hill, Timothy A., Lucke, Andrew J., Craik, David J., Edmonds, David J., Griffith, David A., Rotter, Charles J., Ruggeri, Roger B., Price, David A., Liras, Spiros and Fairlie, David P. (2014). Improving on nature: making a cyclic heptapeptide orally bioavailable. Angewandte Chemie - International Edition, 53 (45), 12059-12063. doi: 10.1002/anie.201405364

  • Journal Article: Constraining cyclic peptides to mimic protein structure motifs

    Hill, Timothy A., Shepherd, Nicholas E., Diness, Frederik and Fairlie, David P. (2014). Constraining cyclic peptides to mimic protein structure motifs. Angewandte Chemie (International Edition), 53 (48), 13020-13041. doi: 10.1002/anie.201401058

  • Journal Article: Pathway-selective antagonism of proteinase activated receptor 2

    Suen, J. Y., Cotterell, A., Lohman, R. J., Lim, J., Han, A., Yau, M. K., Liu, L., Cooper, M. A., Vesey, D. A. and Fairlie, D. P. (2014). Pathway-selective antagonism of proteinase activated receptor 2. British Journal of Pharmacology, 171 (17), 4112-4124. doi: 10.1111/bph.12757

  • Journal Article: Stereoelectronic effects dictate molecular conformation and biological function of heterocyclic amides

    Reid, Robert C., Yau, Mei-Kwan, Singh, Ranee, Lim, Junxian and Fairlie, David P. (2014). Stereoelectronic effects dictate molecular conformation and biological function of heterocyclic amides. Journal of the American Chemical Society, 136 (34), 11914-11917. doi: 10.1021/ja506518t

  • Journal Article: Complement c5a receptor facilitates cancer metastasis by altering t-cell responses in the metastatic niche

    Vadrevu, Saurya Kumari, Chintala, Navin K., Sharma, Sharad K., Sharma, Priya, Cleveland, Clayton, Riediger, Linley, Manne, Sasikanth, Fairlie, David P., Gorczyca, Wojciech, Almanza, Othon, Karbowniczek, Magdalena and Markiewski, Maciej M. (2014). Complement c5a receptor facilitates cancer metastasis by altering t-cell responses in the metastatic niche. Cancer Research, 74 (13), 3454-3465. doi: 10.1158/0008-5472.CAN-14-0157

  • Journal Article: T-cell activation by transitory neo-antigens derived from distinct microbial pathways

    Corbett, Alexandra J., Eckle, Sidonia B. G., Birkinshaw, Richard W., Liu, Ligong, Patel, Onisha, Mahony, Jennifer, Chen, Zhenjun, Reantragoon, Rangsima, Meehan, Bronwyn, Cao, Hanwei, Williamson, Nicholas A., Strugnell, Richard A., Van Sinderen, Douwe, Mak, Jeffrey Y. W., Fairlie, David P., Kjer-Nielsen, Lars, Rossjohn, Jamie and McClusky, James (2014). T-cell activation by transitory neo-antigens derived from distinct microbial pathways. Nature, 509 (7500), 361-365. doi: 10.1038/nature13160

  • Journal Article: Downsizing a human inflammatory protein to a small molecule with equal potency and functionality

    Reid, Robert C., Yau, Mei-Kwan, Singh, Ranee, Hamidon, Johan K., Reed, Anthony N., Chu, Peifei, Suen, Jacky Y., Stoermer, Martin J., Blakeney, Jade S., Lim, Junxian, Faber, Jonathan M. and David P. Fairlie, (2013). Downsizing a human inflammatory protein to a small molecule with equal potency and functionality. Nature Communications, 4 (2802) 2802, 1-9. doi: 10.1038/ncomms3802

View all Publications

Grants

View all Grants

Supervision

  • Peptide modulators for drug discovery

    Doctor Philosophy

  • Novel chemical approaches to drugs that selectively target immune cells

    Doctor Philosophy

  • New strategies in heterocyclic chemistry for drug discovery

    Doctor Philosophy

View all Supervision

Available Projects

  • Targeting strategies for drug design

    Selective binding of small molecules with proteins underpins most drug discovery. However, while a compound can be devised to interact with a single protein, this cannot drive the molecule into a specific location where functional modulation of the target protein only at that location is desired for therapy. Instead, designed compounds usually bind to the protein wherever it is expressed in the body and this can be deterimental to normal healthy physiology. This project will investigate a number of promising new approaches to directing protein-binding compounds to specific compartments of cells and organisms. It will require a combination of organic synthesis, medicinal chemistry, molecular modelling and chemical biology. The new approaches will be tested and optimised with the goal of inhibiting or activating desired proteins in specific compartments in order to modulate disease-causing protein functions without altering normal healthy physiology. Achieving these aims will require enthusiasm, a high degree of self-motivation, lateral thinking, strong chemical knowledge and hands-on skills in organic synthesis (solution and solid phase), NMR characterisation (including 2D NMR structure analysis), HPLC purification, mass spectrometry, and computer modelling. Some knowledge of enzyme assays and cell biology would be an advantage. The long term goal is to design new compounds and profile them for selective effects on target genes/proteins/cells/rodent models of inflammatory diseases and cancer. Outcomes will include new knowledge of protein function in disease; greater understanding of medicinal and organic chemistry in drug design, drug targeting, mechanisms and effectiveness of drug action; patentable methods and bioactive compounds; and new experimental leads to new medicines for development towards the clinic.

View all Available Projects

Publications

Featured Publications

Book Chapter

  • Thiazoles in peptides and peptidomimetics

    Mak, Jeffrey Y. W., Xu, Weijun and Fairlie, David P. (2017). Thiazoles in peptides and peptidomimetics. Peptidomimetics I. (pp. 235-266) edited by William D. Lubell. Cham, Switzerland: Springer. doi: 10.1007/7081_2015_176

  • Helix-constrained nociceptin peptides are potent agonists and antagonists of ORL-1 and nociception

    Lohman, Rink-Jan, Harrison, Rosemary S., Ruiz-Gomez, Gloria, Hoang, Huy Ngoc, Shepherd, Nicholas E., Chow, Shiao, Hill, Timothy A., Madala, Praveen K. and Fairlie, David P. (2015). Helix-constrained nociceptin peptides are potent agonists and antagonists of ORL-1 and nociception. Nociceptin opioid. (pp. 1-55) edited by Gerald Litwack. Maryland Heights, MO, United States: Academic Press. doi: 10.1016/bs.vh.2014.10.001

  • Recent advances in β-Strand mimetics

    Loughlin, Wendy A. and Fairlie, David P. (2011). Recent advances in β-Strand mimetics. Amino acids, peptides and proteins in organic chemistry: protection reactions, medicinal chemistry, combinatorial synthesis. (pp. 129-147) edited by Andrew B. Hughes. Somerset, NJ, United States: Wiley-VCH. doi: 10.1002/9783527631827.ch3

  • Tumor-associated antigenic peptides as vaccine candidates

    Hans, Dhiraj, Young, Paul R. and Fairlie, David P. (2009). Tumor-associated antigenic peptides as vaccine candidates. Tumor-associated antigens. (pp. 303-316) edited by Olivier Gires and Barbara Seliger. Weinheim, Germany: Wiley - VCH Verlag. doi: 10.1002/9783527625970.ch17

  • Parallel synthesis af anticancer, antiinflammatory and antiviral agents derived from L- and D- amino acids

    Reid, Robert, C. and Fairlie, David P. (2008). Parallel synthesis af anticancer, antiinflammatory and antiviral agents derived from L- and D- amino acids. High-throughput lead optimisation in drug discovery. (pp. 177-194) edited by Tushar Kshirsagar. Boca Raton, USA: CRC Press.

  • Amyloid peptides and proteins in review

    Harrison, R. S., Sharpe, P. C., Singh, Y. and Fairlie, D. P. (2007). Amyloid peptides and proteins in review. Reviews of physiology, biochemistry and pharmacology. (pp. 1-77) edited by S. G. Amara, B. Bamberg, T. Fleischmann, S. C. Gudermann, S. C. Hebert, R. Jahn, W. J. Lederer, R. Lill, A. Miyajima, S. Offermanns and R. Zechner. Berlin, Germany: Springer. doi: 10.1007/112_2007_0701

  • Discovery of Potent Cyclic Antagonists of Human C5a Receptors

    Taylor, S. M. and Fairlie, D. (2005). Discovery of Potent Cyclic Antagonists of Human C5a Receptors. Structural Biology of the Complement System. (pp. 341-362) edited by I. Morikis and J Lambris. New York: CRC Press, Taylor and Francis.

  • Current approaches to peptidomimetics

    Kelso, M. J. and Fairlie, D. (2003). Current approaches to peptidomimetics. Molecular Pathomechanisms and New Trends in Drug Research. (pp. 579-598) edited by I. Toth and G. Keri. London and New York: Taylor and Francis.

  • Mimicking extended conformations of protease substrates: Designing cyclic peptidomimetics to inhibit HIV-1 protease

    Fairlie, D. P. and Reid, R. C. (1997). Mimicking extended conformations of protease substrates: Designing cyclic peptidomimetics to inhibit HIV-1 protease. Advances in amino acid mimetics and peptidomimetics. (pp. 77-107) London: JAI Press Inc.

Journal Article

Conference Publication

  • Heterocycles for switching GPCR ligand conformation and activity

    Fairlie, David, Reid, Robert, Rowley, Jessica, Wu, Kai-Chen, Yau, Mei-Kwan, Lim, Junxian and Iyer, Abishek (2019). Heterocycles for switching GPCR ligand conformation and activity. National Meeting of the American Chemical Society (ACS), Orlando, FL United States, 31 March-4 April 2019. Washington, DC United States: American Chemical Society.

  • IL-23 co-stimulation drives antigen-specific MAIT cell activation and enables vaccination against bacterial infection

    Wang, H., Kjer-Nielsen, L., Shi, M., Souza, D. C., Pediongco, T., Cao, H., Kostenko, L., Lim, X., Eckle, S., Meeha, B., Wang, B., Zhu, T., Mak, J., Fairlie, D., Teng, M., Rossjohn, J., Yu, D., Groth, B., McCluskey, J., Strugnell, R., Corbett, A. and Chen, Z. (2019). IL-23 co-stimulation drives antigen-specific MAIT cell activation and enables vaccination against bacterial infection. 17th International Congress of Immunology (IUIS), Beijing, China, 19-23 October, 2019. Weinheim, Germany: WILEY. doi: 10.1002/eji.201970400

  • PAR-2 does not contribute to tubular damage or renal fibrosis in the obstructed kidney

    Han, Y., Ma, F., Ozols, E., Chew, P., Vesey, D., Gobe, G., Morais, C., Lohman, R., Suen, J., Fairlie, D. and Nikolic-Paterson, D. (2018). PAR-2 does not contribute to tubular damage or renal fibrosis in the obstructed kidney. 54th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology (ANZSN), Sydney, Australia, 8–12 September 2018. Richmond, VIC, Australia: Wiley-Blackwell. doi: 10.1111/nep.13441

  • RNA-sequencing analysis of biopsies from chronic liver disease patients identifies gene signatures associated with progressive liver disease

    Ramnath, D., Irvine, K., Lukowski, S., Horsfall, L., Loh, K., Clouston, A., Patel, P., Iyer, A., Lampe, G., Stow, J., Schroder, K., Fairlie, D., Powell, J., Powell, E. and Sweet, M. (2018). RNA-sequencing analysis of biopsies from chronic liver disease patients identifies gene signatures associated with progressive liver disease. International Liver Congress (ILC), Paris, France, 11-15 April, 2018. Amsterdam, Netherlands: Elsevier BV. doi: 10.1016/S0168-8278(18)31040-7

  • Recipient mucosal-associated invariant T cells control graft-versus-host-disease within the colon

    Varelias, Antiopi, Bunting, Mark, Ormerod, Kate, Koyama, Motoko, Olver, Stuart, Straube, Jasmin, Kuns, Rachel, Robb, Renee, Henden, Andrea, Cooper, Leanne, Lachner, Nancy, Gartlan, Kate, Lantz, Olivier J., Kjer-Nielsen, Lars, Mak, Jeffrey, Fairlie, David, Clouston, Andrew, McCluskey, James, Rossjohn, Jamie, Lane, Steven, Hugenholtz, Phil and Hill, Geoff (2018). Recipient mucosal-associated invariant T cells control graft-versus-host-disease within the colon. Immunology Meeting, Austin Tx, 4-8 May 2018. Bethesda, MD United States: American Association of Immunologists.

  • Stereoelectronic effects on dienophile separation influence the Diels–Alder synthesis of molecular clefts

    Stoermer, Martin J., Wickramasinghe, Wasantha A., Byriel, Karl A., Hockless, David C. R., Skelton, Brian W., Sobolev, Alexandre N., White, Alan H., Mak, Jeffrey Y. W. and Fairlie, David P. (2018). Stereoelectronic effects on dienophile separation influence the Diels–Alder synthesis of molecular clefts. 2018 Royal Society of Chemistry Twitter Conference, London, United Kingdom (held online), 6-7 March 2018. London, United Kingdom: Royal Society of Chemistry.

  • Activity of the histone deacetylase (HDAC) inhibitor AR-42 in a murine malaria model

    Chua, Ming Jang, Do, Darren, Bachu, Prabhakar, Reid, Robert, Fairlie, David, Skinner-Adams, Tina and Andrews, Kathy (2017). Activity of the histone deacetylase (HDAC) inhibitor AR-42 in a murine malaria model. 66th Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH), Baltimore, MD United States, 5-09 November 2017. Deerfield, IL United States: American Society of Tropical Medicine and Hygiene.

  • Mucosal-associated invariant T cells are an important source of TNF in rheumatoid arthritis

    Jansen, Diahann, Klinken, Elizabeth, Nel, Hendrik, Law, Soi Cheng, Koppejan, Hester, Hameetman, Marjolijn, Liu, Ligong, Corbett, Alexandra, Eckle, Sidonia, Fairlie, David, Toes, Rene E. M., van Gaalen, Floris, Rossjohn, Jamie, McCluskey, James and Thomas, Ranjeny (2017). Mucosal-associated invariant T cells are an important source of TNF in rheumatoid arthritis. 2017 ACR/ARHP Annual Meeting, San Diego, California, 3-8 November 2017. Hoboken, NJ, United States: John Wiley & Sons.

  • Vitamin B2 related molecules that activate T cells

    Mak, Jeffrey, Xu, Weijun, Reid, Robert, Corbett, Alexandra, Meehan, Bronwyn, Wang, Huimeng, Chen, Zhenjun, Rossjohn, Jamie, McCluskey, James, Liu, Ligong and Fairlie, David (2017). Vitamin B2 related molecules that activate T cells. 254th National Meeting and Exposition of the American-Chemical-Society (ACS) on Chemistry's Impact on the Global Economy, Washington DC, USA, 20-24 August 2017. Washington DC, USA: American Chemical Society.

  • Heightened MAIT Cell Sensitivity to MR1 Ligands Could Impact Control of Dysbiosis in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis

    Jansen, Diahann, Klinken, Elizabeth, Nel, Hendrik, Law, Soi Cheng, Benham, Helen, Cummins, Lisa, Brown, Matthew, Kenna, Tony, Liu, Ligong, Fairlie, David, Rossjohn, Jamie, Morrison, Mark, Thomas, Ranjeny, Cuiv, Paraic O., McCluskey, James and Corbett, Alexandra (2016). Heightened MAIT Cell Sensitivity to MR1 Ligands Could Impact Control of Dysbiosis in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis. 2016 ACR/ARHP Annual Meeting, Washington, DC, United States, 11-16 November 2016. Hoboken, NJ, United States: John Wiley & Sons. doi: 10.1002/art.39977

  • T cell activation by pyrimidine derivatives

    Fairlie, David, Liu, Ligong, Mak, Jeffrey and Xu, Weijun (2016). T cell activation by pyrimidine derivatives. WASHINGTON: AMER CHEMICAL SOC.

  • Histone deacetylase 7 (HDAC7) regulates a sub-set of TLR-mediated pro-inflammatory responses in macrophages by both deacetylase-dependent and -independent mechanisms

    Das Gupta, K., Shakespear, M., Tunny, K., Hohenhaus, D., Bokil, J. N., Iyer, A., Fairlie, A. D. and Sweet, J. M. (2016). Histone deacetylase 7 (HDAC7) regulates a sub-set of TLR-mediated pro-inflammatory responses in macrophages by both deacetylase-dependent and -independent mechanisms. International Congress of Immunology (ICI), Melbourne, Australia, 21-26 August 2016. Hoboken, NJ, United States: Wiley-Blackwell.

  • A broad family of MR1-restricted T cells

    Gherardin, N. A., Keller, A. N., Woolley, R. E., Le Nours, J., Ritchie, D. S., Neeson, P. J., Birkinshaw, R. W., Eckle, S. B., Waddington, J. N., Liu, L., Fairlie, D. P., McCluskey, J., Pellicci, D. G., Uldrich, A. P., Rossjohn, J. and Godfrey, D., I (2016). A broad family of MR1-restricted T cells. International Congress of Immunology (ICI), Melbourne Australia, 21-26 August 2016. Germany: Wiley.

  • Common drugs modulate mucosal-associated invariant T cell function

    Keller, A. N., Eckle, S. B. G., Xu, W., Liu, L., Hughes, V. A., Mak, J., Meehan, B., Pediongco, T., Birkinshaw, R. W., Chen, Z., Wang, H., Souza, C., Kostenko, L., Corbett, A. J., Purcell, A. W., Fairlie, D. P., McCluskey, J. and Rossjohn, J. (2016). Common drugs modulate mucosal-associated invariant T cell function. International Congress of Immunology (ICI), Melbourne, VIC, Australia, 21-26 August 2016. Germany: Wiley. doi: 10.1002/eji.201670200

  • Drugs/drug analogues modulate MAIT cell function in an MR1-dependent manner

    Eckle, S. B. G., Keller, A. N., Xu, W., Meehan, B., Pediongco, T., Liu, L., Hughes, V. A., Mak, J. Y. W., Birkinshaw, R. W., Chen, Z., Wang, H., D'Souza, C., Kostenko, L., Corbett, A. J., Purcell, A. W., Fairlie, D. P., Rossjohn, J. and McCluskey, J. (2016). Drugs/drug analogues modulate MAIT cell function in an MR1-dependent manner. International Congress of Immunology (ICI), Melbourne, VIC, Australia, 21-26 August 2016. Weinheim, Germany: Wiley - VCH. doi: 10.1002/eji.201670200

  • MAIT cells: Friend or Foe in recognising microbial vitamin metabolites presented by the MHC-I-related molecule MR1

    McCluskey, J., Corbett, A. J., Eckle, S. B. G., Chen, Z., Wang, H., Sun, S., D'Souza, C., Kostenko, L., Reantragoon, R., Meehan, B., Birkinshaw, R. W., Liu, L., Patel, O., Mahony, J., Cao, H., Jackson, D., Williamson, N. A., Strugnell, R. A., Mak, J. Y. W., Van Sinderen, D., Fairlie, D. P., Kjer-Nielsen, L., Godfrey, D., I and Rossjohn, J. (2016). MAIT cells: Friend or Foe in recognising microbial vitamin metabolites presented by the MHC-I-related molecule MR1. International Congress of Immunology (ICI), Melbourne, Australia, August 21-26, 2016. Weinheim, Germany: Wiley. doi: 10.1002/eji.201670200

  • MR1 is an endoplasmic reticulum-resident sensor of vitamin B metabolites

    McWilliam, H., Eckle, S., Theodossis, A., Liu, L., Chen, Z., Fairlie, D., Strugnell, R., Mintern, J., McCluskey, J., Rossjohn, J. and Villadangos, J. (2016). MR1 is an endoplasmic reticulum-resident sensor of vitamin B metabolites. International Congress of Immunology (ICI), Melbourne, Australia, 21-26 August 2016 . Weinheim, Germany: Wiley.

  • Pharmacological Inhibition of Protease-Activated Receptor 2 (Par2) Reduces Crescent Formation in Rat Anti-Gbm Disease

    Tesch, G., Han, Y., Vesey, D., Gobe, G., Lohman, R., Suen, J., Fairlie, D. and Nikolic-Paterson, D. (2016). Pharmacological Inhibition of Protease-Activated Receptor 2 (Par2) Reduces Crescent Formation in Rat Anti-Gbm Disease. 15th Asian Pacific Congress of Nephrology (APCN) and 52nd ANZSN ASM, Perth, WA, Australia, 17–21 September 2016. Richmond, VIC, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/nep.12887

  • Protease activated-receptor-2 induced inflammation and fibrosis is mediated in part through activation of transforming growth factor-beta signalling

    Owens, E., Iyer, A., Morais, C., Lohman, R., Suen, J., Johnson, D., Nikolic-Paterson, D., Gobe, G., Fairlie, D. and Vesey, D. (2016). Protease activated-receptor-2 induced inflammation and fibrosis is mediated in part through activation of transforming growth factor-beta signalling. The 15th Asian Pacific Congress of Nephrology (APCN) and 52nd ANZSN ASM, Perth Western Australia, 17–21 September 2016. Richmond, VIC, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/nep.12887

  • Thymic precursors to the mucosal-associated invariant T cell lineage

    Godfrey, D., Koay, H. -F, Gherardin, N., Enders, A., Loh, L., Chen, Z., Corbett, A., Eckle, S., Meehan, B., d'Udekem, Y., Konstantinov, I, Lappas, M., Liu, L., Goodnow, C., Fairlie, D., Rossjohn, J., Kedzierska, K., Berzins, S., McCluskey, J., Uldrich, A. and Pellicci, D. (2016). Thymic precursors to the mucosal-associated invariant T cell lineage. International Congress of Immunology (ICI), Melbourne Australia, 21-26 August 2016. HOBOKEN: WILEY-BLACKWELL.

  • T cell activation by transitory neo-antigens derived from distinct microbial pathways

    Birkinshaw, Richard W., Corbetta, Alexandra J., Eckle, Sidonia B. G., Liu, Ligong, Patel, Onisha, Mahony, Jennifer, Chen, Zhenjun, Reantragoon, Rangsima, Meehan, Bronwyn, Cao, Hanwei, Williamson, Nicholas A., Strugnell, Richard A., Van Sinderen, Douwe, Mak, Jeffrey Y. W., Fairlie, David P., Kjer-Nielsen, Lars, Rossjohn, Jamie and McCluskey, James (2015). T cell activation by transitory neo-antigens derived from distinct microbial pathways. 8th International Workshop on Antigen Processing and Presentation, Philadelphia Pa, Jun 10-13, 2014. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD.

  • Potent small agonists of protease activated receptor 2

    Yau, Mei Kwan, Suen, Jacky, Xu, Weijun, Lim, Junxian, Liu, Ligong, Adams, Mark, He, Yaowu, Hooper, John, Reid, Robert and Fairlie, David (2015). Potent small agonists of protease activated receptor 2. WASHINGTON: AMER CHEMICAL SOC.

  • T-cell antigen formed from distinct metabolic pathways

    Mak, Jeffrey, Corbett, Alexandra, Eckle, Sidonia, Birkinshaw, Richard, Liu, Ligong, Patel, Onisha, Mahony, Jennifer, Chen, Zhenjun, Reantragoon, Rangsima, Meehan, Bronwyn, Cao, Hanwei, Williamson, Nicholas, Strugnell, Richard, Van Sinderen, Douwe, Fairlie, David, Kjer-Nielsen, Lars, Rossjohn, Jamie and McCluskey, James (2015). T-cell antigen formed from distinct metabolic pathways. WASHINGTON: AMER CHEMICAL SOC.

  • Antigen-specific MAIT cell subsets involved in TB immunity

    Sakala, Isaac, Kjer-Nielsen, Lars, Eickhoff, Christopher, Wang, Xiaoli, Blazevic, Azra, Liu, Ligong, Fairlie, David, Rossjohn, Jamie, McCluskey, James, Fremont, Daved, Hansen, Ted and Hoft, Daniel (2015). Antigen-specific MAIT cell subsets involved in TB immunity. Annual Meeting of the American-Association-of-Immunologists (IMMUNOLOGY), New Orleans La, May 08-12, 2015. BETHESDA: AMER ASSOC IMMUNOLOGISTS.

  • Cyclic penta- and hexa leucine peptides without N-methylation are orally absorbed

    Kok, Woan Mei, Hill, Timothy A., Lohman, Rink-Jan, Hoang, Huy N., Nielsen, Daniel S., Scully, Conor G., Schroeder, Christina I., Colless, Barbara, Bernhardt, Paul V., Edmonds, David, Griffith, David, Rotter, Charles, Ruggeri, Roger, Price, David, Liras, Spiros, Craik, David and Fairlie, David (2015). Cyclic penta- and hexa leucine peptides without N-methylation are orally absorbed. American Chemical Society Meeting, x, 2015. Washington, DC United States: American Chemical Society.

  • Downsizing Proteins Without Losing Potency or Function

    Fairlie, David P. , Yau, Mei-Kwan , Hamidon, Johan K. , Singh, Ranee , Lim, Junxian , Suen, Jacky Y. , Rowley, Jessica A. , Lohman, Rink-Jan , Stoermer, Martin J. , Iyer, Abishek and Reid, Robert C. (2015). Downsizing Proteins Without Losing Potency or Function. American Peptide Symposium 2015, Orlando , Florida, United States, 20-25 June 2015. American Peptide Society. doi: 10.17952/24APS.2015.016

  • Targeting Host Complement C3a/C5a Receptors to Control of Acute Graft-Versus-Host Disease in Mice

    Hung Nguyen, Heinrichs, Jessica Lauren, Fu, Jianing, Wu, Yongxia, Bastian, David, Schutt, Steven, Daenthanasanmak, Anusara, Dany, Mohammmed, Liu, Chen, Fairlie, David, Tomlinson, Stephen and Yu, Xue-Zhong (2015). Targeting Host Complement C3a/C5a Receptors to Control of Acute Graft-Versus-Host Disease in Mice. 57th Annual Meeting of the American-Society-of-Hematology, Orlando, FL, United States, 5-8 December 2015. Washington, DC, United States: American Society of Hematology.

  • Tetramer identification of functional mouse mucosal associated invariant T (MAIT) cells

    Sakala, Isaac G., Kjer-Nielsen, Lars, Eickhoff, Christopher S., Wang, Xiaoli, Liu, Ligong, Fairlie, David P., Rossjohn, Jamie, McCluskey, James, Hoft, Daniel F. and Hansen, Ted H. (2015). Tetramer identification of functional mouse mucosal associated invariant T (MAIT) cells. 8th International Workshop on Antigen Processing and Presentation, Philadelphia Pa, Jun 10-13, 2014. Oxford United Kingdom: Pergamon Press.

  • Tetramer identification of functional mouse mucosal associated invariant T cells

    Sakala, Isaac, Kjer-Nielsen, Lars, Eickhoff, Christopher, Wang, Xiaoli, Liu, Ligong, Fairlie, David, Rossjohn, Jamie, Hoft, Daniel and Hansen, Ted (2014). Tetramer identification of functional mouse mucosal associated invariant T cells. BETHESDA: AMER ASSOC IMMUNOLOGISTS.

  • Characterization of the alpha-proteobacteria Wolbachia pipientis protein disulphide machinery reveals a regulatory mechanism absent in gamma-proteobacteria

    Walden, Patricia M., Halili, Maria A., Archbold, Julia K., Lindahl, Fredrik, Fairlie, David P., Inaba, Kenji and Martin, Jennifer L. (2014). Characterization of the alpha-proteobacteria Wolbachia pipientis protein disulphide machinery reveals a regulatory mechanism absent in gamma-proteobacteria. 28th Annual Symposium of the Protein-Society, San Diego, California, 27-30 July 2014. Hoboken, NJ, United States : Wiley-Blackwell.

  • Novel inhibitors of DENV NS2B/NS3pro protease

    Chow, Shiao Yun, Stoermer, Martin J., Chappell, Keith J., Young, Paul R. and Fairlie, David P. (2013). Novel inhibitors of DENV NS2B/NS3pro protease. 246th National Meeting of the American-Chemical-Society (ACS), Indianapolis in, Sep 08-12, 2013. WASHINGTON: AMER CHEMICAL SOC.

  • How MAIT cells control the growth of intracellular mycobacteria

    Sakala, Isaac, Yankelevich, Wei-Jen, Kjer-Nielsen, Lars, Fairlie, David, Rossjohn, Jamie, McCluskey, James, Hoft, Daniel and Hansen, Ted (2013). How MAIT cells control the growth of intracellular mycobacteria. 100th Annual Meeting of the American Association of Immunologists, Honolulu Hi United States, May 03-07, 2013. Bethesda, MD United States: American Association of Immunologists.

  • Targeting Histone Deacetylase 1 (Hdac 1) to Suppress Both Inflammation and Bone Loss in Arthritis

    Cantley, M., Fairlie, D., Bartold, M., Marino, V, Gupta, P. and Haynes, D. (2013). Targeting Histone Deacetylase 1 (Hdac 1) to Suppress Both Inflammation and Bone Loss in Arthritis. 54th Annual Scientific Meeting of the Australian Rheumatology Association in conjunction with the Rheumatology Health Professionals Association, Perth, WA Australia, 18 -22 May 2013. Richmond, VIC Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/imj.12139

  • Toward more orally bioavailable inhibitors of phospholipase A(2) GIIA (pla2g2a) to treat chronic inflammation

    Barbero, Sheila, Reid, Robert C., Stoermer, Martin J., Lohman, Rink J. and Fairlie, David P. (2013). Toward more orally bioavailable inhibitors of phospholipase A(2) GIIA (pla2g2a) to treat chronic inflammation. 246th National Meeting of the American-Chemical-Society (ACS), Indianapolis, IN, United States, 8-12 September 2013. Washington, DC, United States: American Chemical Society.

  • Concise synthesis of the thiazole-thiazoline fragment of largazole

    Diness, Frederik, Nielsen, Daniel S. and Fairlie, David P. (2012). Concise synthesis of the thiazole-thiazoline fragment of largazole. 243rd National Spring Meeting of the American-Chemical-Society, San Diego Ca, Mar 25-29, 2012. WASHINGTON: AMER CHEMICAL SOC.

  • Fluorobenzene derivatives as multifunctional tools

    Diness, Frederik, Begtrup, Mikael Begtrup and Fairlie, David P. (2012). Fluorobenzene derivatives as multifunctional tools. 243rd National Spring Meeting of the American-Chemical-Society, San Diego Ca, Mar 25-29, 2012. WASHINGTON: AMER CHEMICAL SOC.

  • Ligand-induced dimerisation of the complement C5aR and C5L2 receptors by C5a but not C5a-des Arg

    Croker, Daniel E., Halai, Reena, Fairlie, David P. and Cooper, Matthew A. (2012). Ligand-induced dimerisation of the complement C5aR and C5L2 receptors by C5a but not C5a-des Arg. XXIV International Complement Workshop (ICW), Crete, Greece, 10-15 October 2012. Jena, Germany: Urban und Fischer Verlag. doi: 10.1016/j.imbio.2012.08.152

  • Shedding light on MHC class I antigen loading: A UV-labile peptide ligand approach

    Theodossis, Alex, Ruiz-Gomez, Gloria, Gibb, Andrew, Welland, Andrew, Jones, Paul, Fairlie, David and Rossjohn, Jamie (2012). Shedding light on MHC class I antigen loading: A UV-labile peptide ligand approach. 7th International EMBO Workshop on Antigen Presentation and Processing, Amsterdam, Netherlands, 24-27 April 2012. Oxford, United Kingdom: Pergamon. doi: 10.1016/j.molimm.2012.02.094

  • Shedding light on MHC class I antigen loading: a UV-labile peptide ligand approach

    Theodossis, A., Ruiz-Gomez, G., Gibb, A., Welland, A., Jones, P., Fairlie, D. and Rossjohn, J. (2012). Shedding light on MHC class I antigen loading: a UV-labile peptide ligand approach. 32nd European Peptide Symposium "Peptides 2012", Athens, Greece, 02-07 September 2012. West Sussex, United Kingdom: John Wiley and Sons. doi: 10.1002/psc.2447

  • Inhibiting Histone Deacetylases Expressed in Human Periodontal Tissues Prevents Bone Loss in An Animal Model of Periodontal Disease

    Cantley, M. D., Fairlie, D. P., Bartold, P., Marino, V. and Haynes, D. R. (2011). Inhibiting Histone Deacetylases Expressed in Human Periodontal Tissues Prevents Bone Loss in An Animal Model of Periodontal Disease. IOF Regionals 2nd Asia-Pacific Osteoporosis and Bone Meeting / ANZBMS Annual Scientific Meeting held with the JSBMR, Gold Coast Australia, Sep 04-08, 2011. LONDON: SPRINGER LONDON LTD.

  • Novel agonists and antagonists for protease activated receptor 2

    Yau, Annika M., Liu, Ligong, Reid, Robert C., Barry, Grant D., Suen, Jacky Y., Lohman, Rink-Jan, Le, Giang T., Cotterell, Adam and Fairlie, David P. (2011). Novel agonists and antagonists for protease activated receptor 2. National Meeting of the American Chemical Society (242nd, ACS, 2011), Denver, CO, U.S.A., 28 August-1 September 2011. WASHINGTON: AMER CHEMICAL SOC.

  • Towards orally bioavailable peptides and peptidomimetics

    Fairlie, David P., Stoermer, Martin, Lucke, Andrew, Lohman, Rink-Jan, Liu, Ligong and Ruiz-Gomez, Gloria (2011). Towards orally bioavailable peptides and peptidomimetics. 241st National Meeting and Exposition of the American-Chemical-Society (ACS), Anaheim, CA, United States, 27-31 March 2011. Washington, DC, United States: American Chemical Society.

  • Modelling of the C5a receptor by iterative mutation

    Holt, J. R., Monk, P. N., Fairlie, D. P. and Madala, P. Kumar (2010). Modelling of the C5a receptor by iterative mutation. 23rd International National Complement Workshop, New York Ny, Aug 01-05, 2010. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD. doi: 10.1016/j.molimm.2010.05.061

  • A Novel Protease-Activated Receptor-2 Antagonist Targeting Inflammation and Proliferation in Human Renal Tubular Epithelial Cells

    Vesey David A., Suen, Jacky Yung, Johnson, David W. and Fairlie, David (2010). A Novel Protease-Activated Receptor-2 Antagonist Targeting Inflammation and Proliferation in Human Renal Tubular Epithelial Cells. Kidney Week, American society of Nephrology, Denver Colorado USA, November 16 - 21. Journal of the American Society of Nephrology:

  • Potent inhibitors of West Nile Virus NS2B/NS3 protease

    Chappell, K. J., Fairlie, D. P., Gan, C. H., Gupta, P. K., Hu, S., Jensen, C. M., Liebscher, S., Martin, J. L., Robin, G., Stoermer M. J., Xu, W. and Young, P. R. (2010). Potent inhibitors of West Nile Virus NS2B/NS3 protease. 6th General Meeting of the International Proteolysis Society, Gold Coast, QLD, Australia, 26-30 October 2009. Berlin, Germany: Walter De Gruyter.

  • Protease-activated receptor-2 and renal carcinogenesis

    Vesey, D., Rajandram, R., Blakeney, J., Suen, J., Johnson, D., Fairlie, D. and Gobe, G. (2010). Protease-activated receptor-2 and renal carcinogenesis. 46th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology, Perth Convention and Exhibition Centre, Perth, Western Australia, 12-15 September 2010. Richmond, Vic., Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/j.1440-1797.2010.01377_1.x

  • Sneaking up on West Nile Virus NS2B/NS3 protease subcellular activity utilising dye-quenched substrates

    Liebscher, Susan, Chappell, K. J., Stoermer, Martin J., Watterson, Daniel, Webb, Richard I., Khromykh, Alexander A., Fairlie, David P. and Young, Paul R. (2010). Sneaking up on West Nile Virus NS2B/NS3 protease subcellular activity utilising dye-quenched substrates. PlusStrand 2010: The Ninth International Symposium on Positive-Strand RNA Viruses, Atlanta, GA, U.S.A., 17-21 May 2010.

  • Inhibition of both class I and class II histone deacetylases is required to effectively inhibit osteoclast bone resorption in vivo and in vitro

    Cantley, M. D., Fairlie, D. P., Bartold, M. P., Rainsford, K. D. and Haynes, D. R. (2009). Inhibition of both class I and class II histone deacetylases is required to effectively inhibit osteoclast bone resorption in vivo and in vitro. 2nd Joint Meeting of the International-Bone-and-Mineral-Society/Australian-New-Zealand-Bone-and-Mineral-Society, Sydney Australia, Mar 21-25, 2009. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/j.bone.2009.01.292

  • Antiviral activity in cell culture of potent inhibitors targeting the West Nile Virus NS2B/NS3 protease

    Liebscher, S., Chappell, K.J., Stoermer, M.J., Fairlie, D.P. and Young, P.R (2009). Antiviral activity in cell culture of potent inhibitors targeting the West Nile Virus NS2B/NS3 protease. 6th General Meeting of the International Proteolysis Society, Gold Coast , QLD, Australia, 26-30 October, 2009.

  • Regulating protein and peptide activated GPCRs

    Fairlie, David P., Madala, Praveen K., Stoermer, Martin J., Suen, Jacky, Barry, Grant and Lohman, Rink-Jan (2009). Regulating protein and peptide activated GPCRs. 229th National Meeting of the American Chemical Society, San Diego, California, 13-17 March 2005. Washington DC, United States: American Chemical Society.

  • COMP 264-Unraveling the mechanism of antagonism for human C5a receptor: Comparison of three structurally different antagonists

    Madala, P. K., Stoermer, M., Tyndall, J. D. A., Monk, P. N., Higginbottom, A. and Fairlie, D. P. (2008). COMP 264-Unraveling the mechanism of antagonism for human C5a receptor: Comparison of three structurally different antagonists. 236th National Meeting of the American Chemical Society, Philadelphia, USA, 17-21 August, 2008. Washington, D. C., USA: American Chemical Society.

  • MEDI 256-Activation and inhibition of latent serine proteases, complement factors B and C2

    Fairlie, DP, Le, GT, Halili, M, Ruiz-Gomez, G and Abbenante, J (2008). MEDI 256-Activation and inhibition of latent serine proteases, complement factors B and C2. 236th National Meeting of the American Chemical Society, Philadelphia PA, 17-21 August 2008. Atlanta, GA, USA: The American Chemical Society.

  • Plasmodium falciparum histone deacetylases: Enzymes involved in gene regulation as new antimalarial drug targets

    Andrews, Kathy T., Tran, Thanh N., Lucke, Andrew, Kahnberg, Pia, Lee, G. T., Skinner-Adams, Tina, Gardiner, Donald L. and Fairlie, David P. (2007). Plasmodium falciparum histone deacetylases: Enzymes involved in gene regulation as new antimalarial drug targets. 56th Annual Meeting of the American-Society-of-Tropical-Medicine-and-Hygiene, Philadelphia, PA United States, 04-08 November 2007. Deerfield, IL United States: American Society of Tropical Medicine and Hygiene.

  • Discussion

    Rice, Charles, Heinz, Franz X., Kuhn, Richard, Harris, Eva, Fairlie, David, Young, Paul, Flamand, Marie, Zinkernagel, Rolf, Halstead, Scott, Evans, Thomas G., Jans, David A. and Screaton, Gavin (2006). Discussion.

  • Discussion

    Rice, Charles, Padmanabhan, R. Pad, Canard, Bruno, Vasudevan, Subhash, Satchidanandam, Vijaya, Fairlie, David, Gamarnik, Andrea and Kuhn, Richard (2006). Discussion.

  • Discussion

    Fairlie, David, Gubler, Duane J., Holmes, Edward, Halstead, Scott, Hombach, Joachim, Harris, Eva, Hibberd, Martin, Vasudevan, Subhash, Evans, Thomas G., Keller, Thomas, Gu, Feng, Stephenson, John, Canard, Bruno, Malasit, Prida and Zinkernagel, Rolf (2006). Discussion.

  • Discussion

    Rice, Charles, Hibberd, Martin, Gu, Feng, Harris, Eva, Jans, David A., Farrar, Jeremy, Vasudevan, Subhash, Evans, Thomas G., Holmes, Edward, Fairlie, David and Keller, Thomas (2006). Discussion. Novartis Foundation.

  • Discussion

    Young, Paul, Keller, Thomas, Padmanabhan, R. Pad, Fairlie, David, Hibberd, Martin, Rice, Charles, Canard, Bruno, Vasudevan, Subhash, Screaton, Gavin, Harris, Eva, Gu, Feng, Halstead, Scott, Farrar, Jeremy, Holmes, Edward, Malasit, Prida and Evans, Thomas G. (2006). Discussion. Novartis Foundation.

  • Discussion

    Harris, Eva, Screaton, Gavin, Farrar, Jeremy, Hombach, Joachim, Halstead, Scott, Rice, Charles, Holmes, Edward, Satchidanandam, Vijaya, Young, Paul, Zinkernagel, Rolf, Flamand, Marie, Malasit, Prida and Fairlie, David (2006). Discussion. Novartis Foundation.

  • General discussion I

    Rice, Charles, Heinz, Franz X., Young, Paul, Kuhn, Richard, Neyts, Johan, Keller, Thomas, Fairlie, David, Guber, Duane J. and Screaton, Gavin (2006). General discussion I.

  • MEDI 180-Effects of cyclization constraints on helix/turn peptide structures

    Beyer, Renee L., Hoang, Huy N., Le, Giang T. and Fairlie, David P. (2006). MEDI 180-Effects of cyclization constraints on helix/turn peptide structures. WASHINGTON: AMER CHEMICAL SOC.

  • MEDI 181-Alpha helix induction in HIV REV34-50 by N-terminal nucleators

    Beyer, Renee L., Kelso, Michael J., Reid, Robert C., Le, Giang T. and Fairlie, David P. (2006). MEDI 181-Alpha helix induction in HIV REV34-50 by N-terminal nucleators. WASHINGTON: AMER CHEMICAL SOC.

  • Defining the ligand binding site on the human C5a receptor

    Monk, Peter N., Higginbottom, Adrian, Madala, Praveen K., Tyndall, Joel D. A., Stoermer, Martin and Fairlie, David P. (2006). Defining the ligand binding site on the human C5a receptor. 231st National Meeting of the American-Chemical-Society, Atlanta Ga, Mar 26-30, 2006. WASHINGTON: AMER CHEMICAL SOC.

  • Alpha helix induction in HIV REV34-50 by N-terminal nucleators

    Beyer, Renee L., Kelso, Michael J., Reid, Robert C., Le, Giang T. and Fairlie, David P. (2006). Alpha helix induction in HIV REV34-50 by N-terminal nucleators. 232nd ACS National Meeting, San Francisco, CA, U.S.A., 10-14 September, 2006. American Chemical Society. doi: 10.1021/cen-v084n034.p055

  • Defining the ligand binding site on the human C5a receptor

    Monk, Peter N., Higginbottom, Adrian, Madala, Praveen K., Tyndall, Joel D. A., Stoermer, Martin and Fairlie, David P. (2006). Defining the ligand binding site on the human C5a receptor. The 231st ACS National Meeting, Atlanta, GA, U.S.A., 26-30 March 2006. Washington, D.C.: American Chemical Society.

  • Developing antiviral targets for RSV via mutational analysis of HRB and HRC domains using a novel fusion assay system

    Desai, A., Khlentzos, A., Shepherd, N., Hoang, H. N., Letouze, E., Fairlie, D. and Young, P. R. (2006). Developing antiviral targets for RSV via mutational analysis of HRB and HRC domains using a novel fusion assay system. 13th International Conference of Negative Strand Viruses, Salamanca, 17-22 June, 2006.

  • Final discussion

    Ng Mah Lee, Mary, Rice, Charles, Fairlie, David, Zinkernagel, Rolf, Young, Paul, Neyts, Johan, Hibberd, Martin, Holmes, Edward, Heinz, Franz X. and Stephenson, John (2006). Final discussion. Novartis Foundation Symposium 277: New treatment strategies for Dengue and other flaviviral diseases, *, 2006. John Wiley & Sons.

  • Investigation of the West Nile virus NS3 protease by tandem use of site-directed mutagenesis and substrate modification

    Chappell, K. J., Stoermer, M J, Fairlie, D and Young, P R (2006). Investigation of the West Nile virus NS3 protease by tandem use of site-directed mutagenesis and substrate modification. Australian Society for Microbiology Annual Scientific Meeting, Gold Coast, Qld, 2-6 July, 2006.

  • Multiple targets for antiviral inhibitors

    Young, P. R., Chappell, K. J., Stoermer, M. J., Fairlie, D., Kampmann, T. and Kobe, B. (2006). Multiple targets for antiviral inhibitors. 7th Asia Pacific Congress of Virology, New Delhi, 13-15 Nov, 2006.

  • New Treatment Strategies for Dengue and other Flaviviral Diseases

    Fairlie, D. (2006). New Treatment Strategies for Dengue and other Flaviviral Diseases. Norvatis foundations Symposium 277 on New Treatment Strategies for Dengue and other Flaviviral Diseases, Singapore, 26-27 September, 2005. Chichester, UK: John Wiley and Sons.

  • Peptide bundles: Loops, helices, strands and sheets

    Fairlie, D., Singh, Y. and Sharpe, P. C. (2006). Peptide bundles: Loops, helices, strands and sheets. The American Chemical Society Meeting 2006, Atlanta, GA, USA, 26 -30 March, 2006. Washington: American Chemical Society.

  • Alpha-helix induction in short peptides using metal clips

    Ma, M. T., Hoang, H. N., Beyer, R. L., Bryant, G. K., Appleton, T. G. and Fairlie, D. (2005). Alpha-helix induction in short peptides using metal clips. International Chemical Congress of Pacific Basin Societies (Pacifichem2005), Honolulu, Hawaii, 15 - 20 December 2005. WASHINGTON: AMER CHEMICAL SOC.

  • Development of a catalytically active recombinant West Nile NS3 protease and the identification of key enzyme-substrate interactions by site-directed mutagenesis

    Chappell, K. J., Stoermer, M. J., Fairlie, D. and Young, P. R. (2005). Development of a catalytically active recombinant West Nile NS3 protease and the identification of key enzyme-substrate interactions by site-directed mutagenesis. 30th Lorne Conference on Protein Structure & Function, Lorne, 6-10 Feb, 2005.

  • Development of a catalytically active recombinant West Nile NS3 protease and the identification of key enzyme-substrate interactions by site-directed mutagenesis

    Chappell, K. J., Stoermer, M. J., Fairlie, D. and Young, P. R. (2005). Development of a catalytically active recombinant West Nile NS3 protease and the identification of key enzyme-substrate interactions by site-directed mutagenesis. International Congress of Virology, San Francisco, 23-27 July, 2005.

  • Development of a catalytically active recombinant West Nile virus NS3 protease and the identification of key enzyme-substrate and enzyme-cofactor interactions by site-directed mutagenesis

    Chappell, K. J., Stoermer, M. J., Fairlie, D. and Young, P. R. (2005). Development of a catalytically active recombinant West Nile virus NS3 protease and the identification of key enzyme-substrate and enzyme-cofactor interactions by site-directed mutagenesis. 3rd Australian Virology Group Meeting, Phillip Island, Vic., 9-12 Dec, 2005.

  • Modular alpha-helices: conformationally stable cyclic pentapeptides as alpha-turn mimetics

    Shepherd, Nicholas E., Hoang, Huy N., Abbenante, Giovanni and Fairlie, David P. (2005). Modular alpha-helices: conformationally stable cyclic pentapeptides as alpha-turn mimetics. 3rd International Peptide Symposium/28th European Peptide Symposium, Prague, Czech Republic, 5-10 September 2004. Geneva, Switzerland: Kenes INT.

  • Cardiovascular structural and functional adaptations to group IIAsPLA2 inhibition

    Levick, S., Taylor, S. M., Fairlie, D. and Brown, L. C. (2004). Cardiovascular structural and functional adaptations to group IIAsPLA2 inhibition. 2004 ISHR World Congress, Brisbane, Australia, 7-11/8/04. London: Academic Press.

  • Small molecules that mimic components of bioactive protein surfaces

    Fairlie, DP (2004). Small molecules that mimic components of bioactive protein surfaces. Australia: CSIRO Publishing. doi: 10.1071/CH04074

  • Towards Modular Alpha-Helices: Comformationally Stable Cyclic Pentapeptides as Alpha-Turn Mimetics

    Shepherd, N. E., Hoang, H., Abbenante, G. and Fairlie, D. P. (2004). Towards Modular Alpha-Helices: Comformationally Stable Cyclic Pentapeptides as Alpha-Turn Mimetics. 3rd International Peptide Symposium/28th European Peptide Symposium, Prague Czech Republic, Sep 05-10, 2004. GENEVA 1: JOHN WILEY & SONS LTD.

  • Template-assembled peptide loops, helices, sheets and nanofibres

    Fairlie, DP, Singh, Y, Sharpe, P and Stoermer, M (2003). Template-assembled peptide loops, helices, sheets and nanofibres. 225th National Meeting of the American-Chemical-Society, New Orleans Louisiana, Mar 23-27, 2003. WASHINGTON: AMER CHEMICAL SOC.

  • Helix inducing metal clips in short peptides

    Beyer, R. L., Kelso, M. J., Hoang, H. N., Appleton, T. G. and Fairlie, D. (2003). Helix inducing metal clips in short peptides. Proceedings of the First International Symposium on Biomolecuy, Awaji, Japan, 2-5 December, 2003. Tokyo, Japan: Maruzen Co. Ltd..

  • Short peptide alpha helices induced by multiple metal clips

    Hoang, Huy N., Bryant, Gavin K., Kelso, Micheal J., Beyer, Renee L., Appleton, Trevor G. and Fairlie, David P. (2003). Short peptide alpha helices induced by multiple metal clips. 11th International Conference on Biological Inorganic Chemistry, Cairns, Australia, 19-23 July 2003. New York, USA: Elsevier. doi: 10.1016/S0162-0134(03)80638-4

  • Short peptide alpha helices induced by multiple metal clips

    Hoang, Huy N., Bryant, Gavin K., Kelso, Micheal J., Beyer, Renee L., Appleton, Trevor G. and Fairlie, David P. (2003). Short peptide alpha helices induced by multiple metal clips. 11th International Conference on Biological Inorganic Chemistry, Cairns, Australia, 19-23 July, 2003. New York, USA: Elsevier. doi: 10.1016/S0162-0134(03)80638-4

  • Studies of the interaction of potassium(I), calcium(II), magnesium(II) and copper(II) with cyclosporin A

    Gahan, Lawrence R., Cusack, Rodney M., Grondahl, Lisbeth H., Fairlie, David P. and Hanson, Graeme R. (2003). Studies of the interaction of potassium(I), calcium(II), magnesium(II) and copper(II) with cyclosporin A. 11th International Conference on Biological Inorganic Chemistry, New York, USA, 19-23July, 2003. New York, USA: Elseiver. doi: 10.1016/S0162-0134(03)80624-4

  • Template-assembled peptide loops, helices, sheets, and nanofibers

    Fairlie, David P ., Singh, Yogendra, Sharpe, Philip and Stoermer, Martin (2003). Template-assembled peptide loops, helices, sheets, and nanofibers. 225th ACS National Meeting, New Orleans, LA, United States, 23-27 March 2003.

  • Palladium induced alpha helicity in short peptides.

    Kelso, MJ, Hoang, HN, Appleton, TG and Fairlie, DP (2002). Palladium induced alpha helicity in short peptides.. WASHINGTON: AMER CHEMICAL SOC.

  • A new C5a receptor antagonist inhibits monoarticular arthritis in the rat

    Woodruff, T. M., Shiels, I. A., Fairlie, D. and Taylor, S. M. (2001). A new C5a receptor antagonist inhibits monoarticular arthritis in the rat. Complement Assoc. Diseases, Animal Models & Ther. Workshop, Santorini, Greece, 10-14 October, 2001. Aegean Conferences.

  • Construction and characterization of the dengue 2 virus NS3 protease and its mutants

    Fang, N., Arakaki, T., Fairlie, D., Martin, J. L. and Young, P. R. (2001). Construction and characterization of the dengue 2 virus NS3 protease and its mutants. 1st Australian Virology Group Meeting, Fraser Island, Qld, 5-9 December, 2001.

  • Control of peptide conformation by Palladium(II) coordination

    Appleton, T. G., Fairlie, D., Hoang, H. N., Kelso, M., March, D. R. and Oliver, W. (2001). Control of peptide conformation by Palladium(II) coordination. 10th International Conf on Bioinorganic Chemistry, Florence, Italy, 26-31 August, 2001. NEW YORK: ELSEVIER SCIENCE INC.

  • In vitro catalytic activity of recombinant forms of the dengue virus NS3 protease

    Young, P. R., Fang, N., Leung, D., Arakaki, T., Stoermer, M. J., Fairlie, D. and Martin, J. L. (2001). In vitro catalytic activity of recombinant forms of the dengue virus NS3 protease. 6th International Symposium on Positive Strand Viruses, Paris, France, 28 May - 2 June, 2001.

  • Metal clips for folding peptides

    Appleton, T. G., Hoang, H. N., Fairlie, D., Kelso, M. and Bryant, G. K. (2001). Metal clips for folding peptides. World Chemistry Congress, Brisbane, 1-6 July, 2001.

  • Prevention of ischemia/reperfusion injuries in rats by a new small molecule C5a receptor antagonist

    Arumugum, T.V., Shiels, I. A., Fairlie, D. and Taylor, S. M. (2001). Prevention of ischemia/reperfusion injuries in rats by a new small molecule C5a receptor antagonist. Complement Associated Diseases, Animal Models and Ther. W/shop, Santorini, Greece, 10-14 October 2001. Aegean Conferences.

  • Complement and inflammation: New antagonists of C5a receptors.

    Fairlie, DP (2000). Complement and inflammation: New antagonists of C5a receptors.. WASHINGTON: AMER CHEMICAL SOC.

  • Coordination with Pd(en)2+ imposes an a-helical structure on a pentapeptide

    Appleton, T. G., Hoang, H. N. and Fairlie, D. (2000). Coordination with Pd(en)2+ imposes an a-helical structure on a pentapeptide. Pacifichem 2000, Honolulu, Hawaii, 14-19 December, 2000. American Chemical Society.

  • Expression and characterization of a catalytically active form of the Dengue virus NS3 protease

    Young, P. R., Fang, N., Leung, D., Arakaki, T., Fairlie, D. and Martin, J. L. (2000). Expression and characterization of a catalytically active form of the Dengue virus NS3 protease. 1st Int Conf on Dengue and Dengue Haemorrhagic Fever, Chiang Mai, Thailand, 20-24 Nov, 2000.

  • Metallopeptides in Alzheimer's Disease

    Hanson, G. R., Bush, A. R. I., Fairlie, D. and Tyndall, J. (2000). Metallopeptides in Alzheimer's Disease. Brisbane Inorganic Chemistry Symposium, Dept of Chemistry, Uni of Queensland, 30 November 2000. Brisbane (UQ): Dept of Chemistry, UQ.

  • The reaction between metal ions and short peptides

    Hoang, H. N., Appleton, T. G. and Fairlie, D. (2000). The reaction between metal ions and short peptides. IC2000/11RACIC, Canberra, 6-11 Feb, 2000.

  • Towards Arginine Mimetics

    Stoermer, Martin and Fairlie, David (2000). Towards Arginine Mimetics. The First Brisbane Biological and Organic Chemistry Symposium, Griifith University, Brisbane, Queensland, Australia, 27th November 2000. doi: 10.6084/m9.figshare.7836131

  • Cyclic peptides as metal ion receptors

    Cusack, R., Grondahl, L., Abbenante, J., Fairlie, D., Gahan, L. R., Hambley, T. W. and Hanson, G. R. (1999). Cyclic peptides as metal ion receptors. IC'99, Wellington, NZ, 31 January - 4 February 1999. Wellington, NZ: NZ Institute of Chemistry.

  • Homology model of the dengue 2 virus NS3 protease: Interactions with NS2B co-factor

    White, H., Young, P. R., Brinkworth, R. I., Fairlie, D. and Leung, D. D. (1999). Homology model of the dengue 2 virus NS3 protease: Interactions with NS2B co-factor. XIth International Congress of Virology, Sydney, 9-13 August 1999. Sydney: International Union of Microbiological Societies.

  • Modelling Studies Of Molecular Receptors

    Chalmers, David K., Stoermer, Martin J. and Fairlie, David P. (1998). Modelling Studies Of Molecular Receptors. Royal Australian Chemical Institute 16th National Organic Chemistry Conference, Leura, Blue Mountains, New South Wales, 12-17 July 1998.

  • The selective binding of metal ions by tolyporphins

    Appleton, T. G., Prinsep, M. R., Fairlie, D. P., Lane, I. and Hanson, G. R. (1997). The selective binding of metal ions by tolyporphins. XXXI ICCC: International Conference on Coordination Chemistry, Vancouver, BC, Canada, 18–23 August 1996. Triangle Park, NC, U.S.A.: IUPAC Secretariat.

  • Cyclic Peptides as Metal Ion Receptors

    Cusack, R. M., Abernante, J., Gahan, L. R., Fairlie, D. P. and Hanson, G. R. (1996). Cyclic Peptides as Metal Ion Receptors. RACI Inorganic Division, IC '96, Townsville, Queensland, Australia, 30 June - 4 July, 1996.

  • Effects of conformational constraints in cyclic octapeptides of marine origin

    Abbenante, G., Fairlie, D. P., Sokolenko, N., Gahan, L. R., Cusack, R., Hanson, G. R. and Pierens, G. K. (1996). Effects of conformational constraints in cyclic octapeptides of marine origin. 10th Brisbane Organic Chemistry Symposium, Brisbane, QLD, Australia, 29 November 1996.

  • Multifrequency EPR studies of the mono- and bi-nuclear copper(II) complexes formed with the marine cyclic octapeptides patellamide D and ascidiacyclamide

    Hanson, G. R., van den Brenk, A. L., Gahan, L. R., Fairlie, D. P. and Hawkins, C. J. (1996). Multifrequency EPR studies of the mono- and bi-nuclear copper(II) complexes formed with the marine cyclic octapeptides patellamide D and ascidiacyclamide. EPR-95: Electron Paramagnetic Resonance 1995 Satellite Workshop Meeting of the 12th International Society of Magnetic Resonance Conference (ISMAR'95), Sydney, NSW, Australia, 13-15 July 1995. Berlin, Germany: Springer Wien.

  • Multifrequency EPR spectra of Cu(II) and Ag(II) tolyporphins

    Lane, I., Prinsep, M., Hanson, G. R., Appleton, T. G. and Fairlie, D. (1995). Multifrequency EPR spectra of Cu(II) and Ag(II) tolyporphins. ISMAR 95: Twelfth Conference of the International Society of Magnetic Resonance, Sydney, NSW, Australia, 16-21 July 1995. Philadelphia, PA, U.S.A.: International Society of Magnetic Resonance (ISMAR).

  • The selective binding of tolyporphins to metal ions

    Appleton, T. G., Prinsep, M. R., Fairlie, D. P., Lane, I., Hanson, G. R. and Moore, R. E. (1995). The selective binding of tolyporphins to metal ions. 10th National Convention RACI: The Royal Australian Chemical Institute's 10th National Convention: Chemistry Serving Society, Adelaide, SA, Australia, 27 September-2 October 1995. Adelaide, SA, Australia: ICI Australia.

  • CHARACTERIZATION OF TNF-ALPHA-RELATED PEPTIDES BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY MASS-SPECTROMETRY AND HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY TANDEM MASS-SPECTROMETRY

    ALEWOOD, PF, BAILEY, AJ, BRINKWORTH, RI, FAIRLIE, D and JONES, A (1993). CHARACTERIZATION OF TNF-ALPHA-RELATED PEPTIDES BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY MASS-SPECTROMETRY AND HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY TANDEM MASS-SPECTROMETRY. 12Th International Symp On High-Performance Liquid Chromatography of Proteins, Peptides and Polynucleotides, Sydney Australia, Nov 29-Dec 02, 1992. AMSTERDAM: ELSEVIER SCIENCE BV. doi: 10.1016/S0021-9673(99)87020-4

  • Symmetrical and Nonsymmetrical Nonpeptide Inhibitors of Hiv-1 Protease - Naphthalenesulfonic Acid-Derivatives

    Mohan, P, Wong, MF, Verma, S, Huang, PP, Brinkworth, RI and Fairlie, DP (1993). Symmetrical and Nonsymmetrical Nonpeptide Inhibitors of Hiv-1 Protease - Naphthalenesulfonic Acid-Derivatives. WASHINGTON: AMER CHEMICAL SOC.

  • Tautomerism in Amide Complexes

    Fairlie, DP and Woon, TC (1992). Tautomerism in Amide Complexes. WASHINGTON: AMER CHEMICAL SOC.

  • Design and synthesis of new cavitands which are stereochemically rigid, hydrophobic and internally functionalised

    Stoermer, M.J., Wickramasinghe, W., Weerasuria, K.D.V., Fairlie, D., Butler, D. and Warrener, R. (1992). Design and synthesis of new cavitands which are stereochemically rigid, hydrophobic and internally functionalised. Royal Australian Chemical Institute National Conference 1992, Monash University, Melbourne, Australia, 28 Sept - 2 October 1992.

  • Synthesis of cavitands as catalytic environments

    Stoermer, Martin J. and Fairlie, David P. (1991). Synthesis of cavitands as catalytic environments. 12th National Conference of the Royal Australian Chemical Institute, Division of Organic Chemistry, University of Queensland, Australia, 1991.

Other Outputs

Grants (Administered at UQ)

PhD and MPhil Supervision

Current Supervision

  • Peptide modulators for drug discovery

    Doctor Philosophy — Principal Advisor

    Other advisors:

  • Novel chemical approaches to drugs that selectively target immune cells

    Doctor Philosophy — Principal Advisor

    Other advisors:

  • New strategies in heterocyclic chemistry for drug discovery

    Doctor Philosophy — Principal Advisor

    Other advisors:

  • Novel activators and inhibitors of innate immune cells

    Doctor Philosophy — Principal Advisor

    Other advisors:

  • Design and synthesis of novel Major histocompatibility complex class I-Related protein ligands

    Doctor Philosophy — Associate Advisor

    Other advisors:

  • Combating bacterial infections through reprogramming of innate immunity

    Doctor Philosophy — Associate Advisor

    Other advisors:

  • Modulation of innate immune proteins in cancers

    Doctor Philosophy — Associate Advisor

    Other advisors:

Completed Supervision

Possible Research Projects

Note for students: The possible research projects listed on this page may not be comprehensive or up to date. Always feel free to contact the staff for more information, and also with your own research ideas.

  • Targeting strategies for drug design

    Selective binding of small molecules with proteins underpins most drug discovery. However, while a compound can be devised to interact with a single protein, this cannot drive the molecule into a specific location where functional modulation of the target protein only at that location is desired for therapy. Instead, designed compounds usually bind to the protein wherever it is expressed in the body and this can be deterimental to normal healthy physiology. This project will investigate a number of promising new approaches to directing protein-binding compounds to specific compartments of cells and organisms. It will require a combination of organic synthesis, medicinal chemistry, molecular modelling and chemical biology. The new approaches will be tested and optimised with the goal of inhibiting or activating desired proteins in specific compartments in order to modulate disease-causing protein functions without altering normal healthy physiology. Achieving these aims will require enthusiasm, a high degree of self-motivation, lateral thinking, strong chemical knowledge and hands-on skills in organic synthesis (solution and solid phase), NMR characterisation (including 2D NMR structure analysis), HPLC purification, mass spectrometry, and computer modelling. Some knowledge of enzyme assays and cell biology would be an advantage. The long term goal is to design new compounds and profile them for selective effects on target genes/proteins/cells/rodent models of inflammatory diseases and cancer. Outcomes will include new knowledge of protein function in disease; greater understanding of medicinal and organic chemistry in drug design, drug targeting, mechanisms and effectiveness of drug action; patentable methods and bioactive compounds; and new experimental leads to new medicines for development towards the clinic.

This staff member is a UQ Expert for media in the following fields:

Medicinal Chemistry, organic chemistry, biological chemistry, drug design, drug discovery, pharmaceuticals, structural chemistry, structural biology, proteins, peptides, enzymes, biochemistry, signal transduction, molecular pharmacology, experimental pharmacology, pathogenesis, immunology, innate immunity, inflammatory diseases, cancers, metastasis, metabolism, metabolic disease, obesity, type 2 diabetes, cardiovascular disease, respiratory disease, neurodegenerative disease, dementia, Alzheimer's disease, infectious diseases, viral infections, malaria, tropical diseases

They are happy to lend their expertise to your articles or broadcasts and share their research discoveries and insights with the community via media channels.

For additional assistance with story ideas, general advice and information or help with seeking further experts, please email the UQ Media Team or telephone (07) 3365 1120.

Links

ResearcherID: F-8865-2014

ORCID: 0000-0002-7856-8566

Scopus ID: 7007085404

Personal Profile: Link

Unit Links
Other Media
Social Media

Related Resources

Similar Staff
Researchers in Associated Units
Fields of Research